01—Abstract
Summary
Summary of the 8-K filed March 3, 2025. Cited figures are marked; the original filing is the authoritative source.
Humana Inc. (HUM) disclosed in a Regulation FD filing dated March 3, 2025 that members of its senior management team are scheduled to meet with investors and analysts between March 3, 2025 and March 31, 2025.
During these meetings, the Company intends to reaffirm its full-year 2025 guidance of approximately $15.88a in diluted earnings per common share (GAAP EPS) and approximately $16.25 in adjusted earnings per common share (Adjusted EPS). The reaffirmed guidance is consistent with the guidance issued in Humana's press release dated February 11, 2025. The filing presents no new or revised outlook, so investors should view this as a reiteration of previously issued expectations rather than a change in the Company's view of its 2025 performance.
The filing includes a reconciliation from GAAP EPS to Adjusted EPS for FY 2025. The reconciliation adds back approximately $0.49b of amortization of identifiable intangibles and deducts a cumulative net tax impact of non-GAAP adjustments of $(0.12). Management states that it uses Adjusted EPS for planning, decision-making, and determining incentive compensation, and that Adjusted EPS should be considered in addition to, not as a substitute for, GAAP EPS.
02—Key points
Key Highlights
- Humana will reaffirm FY 2025 guidance of approximately $15.88 in diluted GAAP EPS during investor and analyst meetings from March 3 through March 31, 2025.
- Adjusted EPS guidance for FY 2025 is approximately $16.25, also reaffirmed in these meetings.
- The reaffirmed guidance is consistent with the outlook in Humana's February 11, 2025 press release, indicating no change to prior expectations.
- The GAAP-to-Adjusted EPS reconciliation adds approximately $0.49 for amortization of identifiable intangibles.
- A cumulative net tax impact of non-GAAP adjustments of $(0.12) per share is deducted in the reconciliation.
- Management uses Adjusted EPS for planning, decision-making, and determining incentive compensation, and describes it as a measure of core business operations over time.
- The disclosure is made under Item 7.01 (Regulation FD Disclosure), so it is furnished for investor communication rather than reporting a new material event.
03—Questions
Frequently Asked Questions
What full-year 2025 earnings guidance is Humana reaffirming?
Humana intends to reaffirm guidance of approximately $15.88 in diluted GAAP EPS and approximately $16.25 in Adjusted EPS for the year ending December 31, 2025.
Is this filing changing Humana's earnings outlook?
No. The filing states that the reaffirmed guidance is consistent with the guidance issued in Humana's February 11, 2025 press release.
When will management be meeting with investors?
Members of senior management are scheduled to meet with investors and analysts at various meetings between March 3, 2025 and March 31, 2025.
What is the difference between GAAP EPS and Adjusted EPS for 2025?
The filing reconciles the two measures: the guidance of approximately $15.88 in GAAP EPS rises to approximately $16.25 in Adjusted EPS after adding approximately $0.49 of amortization of identifiable intangibles and deducting a cumulative net tax impact of $(0.12).
Why does Humana use Adjusted EPS?
Management believes Adjusted EPS, presented alongside GAAP EPS, gives a more comprehensive view of core operating performance over time. It is also used for planning, decision-making, and determining incentive compensation, and it is meant to supplement rather than replace GAAP EPS.
04—Continue